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LysosomeKufor-Rakeb syndrome (KRS) was originally described as an autosomal recessive form of early-onset
parkinsonism with pyramidal degeneration and dementia. ATP13A2 was identiﬁed as the causative
gene in KRS. ATP13A2 encodes the ATP13A2 protein, which is a lysosomal type5 P-type ATPase, and
ATP13A2 mutations are linked to autosomal recessive familial parkinsonism.
Here, we report that normal ATP13A2 localizes in the lysosome, whereas disease-associated vari-
ants remain in the endoplasmic reticulum. Cathepsin D activity was decreased in ATP13A2-knock-
down cells that displayed lysosome-like bodies characterized by ﬁngerprint-like structures.
Furthermore, an atp13a2 mutation in medaka ﬁsh resulted in dopaminergic neuronal death,
decreased cathepsin D activity, and ﬁngerprint-like structures in the brain. Based on these results,
lysosome abnormality is very likely to be the primary cause of KRS/PARK9.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction heavily contribute to the pathogenesis of this disease [1]. InParkinson’s disease (PD) is one of the most common movement
disorders, and it is caused by loss of dopaminergic neurons. The
molecular mechanisms underlying neuronal degeneration in PD
remain unknown; however, it is now clear that genetic factorsapproximately 10% of patients with clinical features of PD, the dis-
ease state has a strict familial etiology.
PARK9-linked PD is an autosomal recessive early-onset disorder
that is characterized by levodopa-responsive parkinsonism, supra-
nuclear gaze palsy, pyramidal signs, and dementia; this condition
is also called Kufor-Rakeb syndrome (KRS), being named for a con-
sanguineous Jordanian family containing four members with this
disorder [2]. Recently, ATP13A2 was identiﬁed as the causative
gene for KRS/PARK9. The ATP13A2 gene comprises 29 exons that
encode a lysosomal type 5 P-type ATPase with 10 transmembrane
domains [3]. Thus far, eight mutations have been reported in just
ﬁve families and in two additional unrelated patients, and no
neuropathological examination of an autopsy case has been docu-
mented [3–8]. The function of the ATP13A2 protein remains largely
unknown, but it is supposed that ATP13A2 might participate in
autophagic protein degradation via the lysosomal pathway [9].
Here, we established and analyzed a cell culture model of
ATP13A2 knockdown and Atp13a2 mutant medaka ﬁsh to eluci-
date the mechanisms underlying PARK9-associated pathology.
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cathepsin D enzymatic activity, ﬁngerprint-like inclusion body for-
mation, and neuronal death. These ﬁndings indicated that abnor-
malities in lysosome function are the primary defect in KRS/PARK9.2. Results
2.1. Wild-type ATP13A2 localizes to the lysosome, but some disease-
relevant variants localize to the endoplasmic reticulum
To investigate the subcellular localization of ATP13A2, we used
an anti-V5 antibody and antibodies that recognize several mark-
ers of intracellular organelles to double label SH-SY5Y cells that
stably expressed wild-type ATP13A2 fused to the V5 epitope
(WT-V5). The WT-V5 signal largely colocalized with the signal
of cathepsin D, a lysosomal aspartic protease (Fig. 1A and S1).
Additionally, WT-V5 partially overlapped with makers of the Golgi
apparatus (GM130), the late endosome (Rab7) and the autophago-
some (LC3B), but not with the markers of the endoplasmic retic-
ulum (ER) (GRP78), the mitochondria (Tom20), the early
endosome (EEA1 and Rab5), or the exocytotic vesicles (Rab3 and
4) (Fig. 1A, B and S1). GFP signals in SH-SY5Y cells that stably ex-
pressed GFP-tagged wild-type ATP13A2 (GFP-WT) strongly colo-
calized with either of two lysosomal membrane proteins, Lamp2
(Fig. 1A and S1) or Lamp1 (data not shown). Furthermore, immu-
noelectron microscopy using ultrathin cryosections of GFP-WT
SH-SY5Y cells conﬁrmed that gold particles labeling GFP-WT (ar-
row head: 10 nm gold) and those labeling Lamp1 (arrow: 5 nm
gold) co-localized on the lysosomal membrane (Fig. 1C). These
data indicated that ATP13A2 is a resident protein of the lysosomal
membrane.
Thus far, eight disease-associated mutations have been identi-
ﬁed in the ATP13A2 gene, including one that we described initially
[3–8]. To determine whether the mutant proteins were mislocal-
ized and whether any such mislocalization has etiological impor-
tance, we assessed the subcellular localization of ﬁve pathogenic
protein variants (Fig. 2A). These mutants were each tagged with
a V5 epitope and then transiently transfected into SH-SY5Y cells.
To, ﬁrst, characterize the subcellular distribution of KRS mutants,
we separated cell homogenates by Percoll density gradient centri-
fugation. This Percoll gradient system separates dense lysosomes
(near bottom) from lighter particles such as ER. We found that
WT-V5 was mainly co-fractionated with lysosomal component
(Lamp1 and cathepsin D; Fraction No. 13–16, Fig. 2B). However,
an ATP13A2 variant that lacks exon 13 (1306 + 5G?A) but main-
tains the reading frame was co-fractionated not with lysosomal
proteins but with GRP78 (Fraction No. 2–8, Fig. 2B): this ﬁnding
indicated that the protein variant accumulated in the ER. Some
other ATP13A2 pathogenic variants (F182L and G504R) also accu-
mulated in the ER in a manner similar to the 1306 + 5G?A variant.
In contrast, the other two pathogenic variants (T12M and G533R)
were co-fractionated with lysosomal components, as was the WT
protein. To, further, conﬁrm the subcellular localization, we carried
out double ﬂuorescence immunocytochemistry of permeabilized
SH-SY5Y cells by staining KRS mutants (V5), the ER marker
(GRP78), the lysosomal marker (cathepsin D) and the mitochondria
marker (Tom20). Along with immunoblotting of Percoll density
gradient fractionation, immunoﬂuorescence studies showed
1306 + 5G?A mutant, F182L and G504R colocalized with GRP78
and the other two variants (T12M and G533R) colocalized with
cathepsin D as already reported [10–14] (Fig. 2C and S1). The
expression levels of ATP13A2 mutant proteins that accumulated
in the ER (F182L, G504R, and 1306 + 5G?A) were lower than that
of the WT protein and MG132 inhibited degradation of the all
ATP13A2 variants as well as that of the WT protein (Fig. 2D).2.2. Stable knockdown of ATP13A2 induces cathepsin D deﬁciency and
structures that resemble neuronal ceroid-lipofuscinosis deposits
To assess whether the loss of normal ATP13A2 functions has a
causal role in PD pathogenesis, the expression of endogenous
ATP13A2 was suppressed in SH-SY5Y cells by gene knockdown.
By using antibodies that we generated (Fig. 3A), we showed that
endogenous ATP13A2 protein levels in SH-SY5Y cells that stably
expressed ATP13A2 shRNA (ATP13A2shRNA-1 or -2) were efﬁ-
ciently suppressed (Fig. 3B). Water soluble Tetrazolium salts
(WST)-8 assay demonstrated that ATP13A2 knockdown caused a
signiﬁcant reduction of the cell growth in SH-SY5Y cells (Fig. 3B).
Next, we determined the distribution and the morphology of lyso-
somes in SH-SY5Y cells subjected to ATP13A2 knockdown. Immu-
nostaining of cathepsin D and Lamp2 indicated that ATP13A2
deﬁciency led to the assembly of lysosomes in the perinuclear re-
gion and decreased cathepsin D staining (Fig. S2). The protein
amount of full length (52-kDa), immature (44-kDa) and mature
(32-kDa) forms of cathepsin D of the cells expressing ATP13A2
shRNAs were all decreased together with the enzyme activity
(Fig. 3C). To show the reduction of cathepsin D activity was indeed
induced by the reduction of ATP13A2, not by the non-speciﬁc effect
of shRNA, we generated shRNA-resistant species of ATP13A2. SH-
SY5Y cells stably expressing ATP13A2 shRNAs that were transfec-
ted with shRNA resistant ATP13A2 showed comparable cathepsin
D activity to the controls (Fig. S3A). The activity and amount of ma-
ture forms (25-kDa) of cathepsin B and L were also decreased in the
knockdown cells line by ATP13A2 shRNA-1, but not shRNA-2, sug-
gesting that the loss of ATP13A2 principally gives rise to the reduc-
tion of cathepsin D (Fig. 3C). Finally, analysis via transmission
electron microscopy revealed that lysosome-like bodies became
more numerous in ATP13A2 shRNAs expressing cells and that very
immense high density structure appeared adjacent to the nucleus
in these cells (Fig. 3D: a–h). High-magniﬁcation images revealed
that the abnormal structures in these cells included ﬁngerprint
proﬁles-like structure (Fig. 3D: e), and these structures were very
similar to the structure of the neurons in mice lacking cathepsin
D [15]. The levels of LC3-II, autophagosome marker, in shRNA-1
transfected cells were increased (Fig. 3E) and p62 a substrate of
autophagic degradation, was accumulated in both of the shRNA
expressing lines (Fig. S3B), suggesting that an appearance of abnor-
mal structure induced by ATP13A2 deﬁciency might be involved
with impaired lysosomal proteolysis. Taken together, these ﬁnd-
ings indicated that loss of ATP13A2 led to lysosomal pathology
and, more speciﬁcally, a reduction in cathepsin D activity.
2.3. Generation of an Atp13a2 mutant medaka ﬁsh
Next, we generated and evaluated medaka ﬁsh with an Atp13a2
mutation to investigate the mechanism of KRS/PARK9-associated
neurodgeneration in vivo. The draft of the medaka genome con-
tains only one identiﬁable ortholog of the human ATP13A2 gene.
We cloned the medaka atp13a2 gene by RT-PCR and RACE, and it
encoded a protein consisting of 1159 amino acids. The amino-acid
sequence showed 51.3% homology to human ATP13A2 protein
(Fig. S4A). To characterize medaka atp13a2 expression, we used
in situ hybridization to visualize medaka atp13a2mRNA. No signal
was observed with the sense RNA probe. However, the anti-sense
RNA probe resulted in diffuse signals in the gray matter of medaka
brain (Fig. 4A). The telencephalon and diencephalon that contain
the putative striatum and many dopaminergic neurons, respec-
tively, were intensely labeled by the anti-sense probe. The optic
tectum was also intensely labeled, but the hindbrain and spinal
cord were scarcely labeled (Fig. 4A).
We then used TILLING (Targeting Induced Local Lesions In Gen-
omes) method to generate an Atp13a2 mutant ﬁsh [16]. We
Fig. 1. Wild-type ATP13A2 localizes at lysosomal membranes. (A and B) WT-V5 and GFP-WT fusion proteins consistently co-localizes with Lamp2 and cathepsin D.
Additionally, WT-V5 partially overlapped with GM130, Rab7 and LC3B. (Scale bar; 10 lm). (C) Immunoelectron microscopy using ultrathin cryosections. Double
immunostaining of GFP-ATP13A2 (gold particles, 10 nm in diameter (open arrowheads)) and Lamp1 (gold particles, 5 nm in diameter (arrows)). Both types of immuno-gold
label clearly localizes along the membranes around lysosomes (asterisks). (Scale bar; 0.5 lm).
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mutagenized medaka library, and identiﬁed one mutation ‘‘IVS13,
T-C, +2’’ that resulted in an aberrant splice donor site (Fig. 4B). The
IVS13, T-C, +2 mutant from this strain was subjected to six sequen-
tial backcrosses to generate themutant used in the following exper-
iments. A cross between heterozygous ‘‘IVS13, T-C, +2’’ mutant pair
resulted in wild-type ﬁsh (WT/WT), heterozygous mutants (WT/
mt), and homozygous mutants (mt/mt) in Mendelian ratios. RT-
PCR analysis revealed an abnormal splice variant in the WT/mt
andmt/mtmedaka (Fig. 4C), and the sequence of these PCRproductsindicated that exon 13 was skipped in the mutant mRNAs (Fig. 4D).
Surprisingly, this abnormal splicing pattern was almost identical to
that in the human KRS/PARK9 patient [3], in which the 111-bp exon
13 is skipped (Fig. S4B). Real-time PCR showed a marked reduction
(17.8%) in the normal atp13a2 mRNA in the mt/mt medaka brain
(Fig. 4E).We therefore concluded thatwe had succeeded in identify-
inganAtp13a2mutant inmedaka, and thismutationwas similar to a
pathogenic KRS/PARK9 mutation in human.
Atp13a2 mutant medaka ﬁsh grew normally during early
development without any obvious morphological abnormalities.
Fig. 2. Characterization of subcellular localization of KRS mutants. (A) Schematic diagram of disease-relevant mutants of ATP13A2 used in this study. (B) Percoll gradient
fractionation of ATP13A2 protein. The graphs indicate densitometry of bands. This Percoll gradient system separates dense lysosomes (near bottom, Fraction 13–16) from
lighter particles such as ER (Fraction 2–8). (C) Double immunoﬂuorescence studies for KRS mutants. Colocalization of T12M or G533R with cathepsin D, a lysosomal protein, is
observed. Other mutants localizes with GRP78, a resident ER chaperone protein. (D) Protein blot analysis of ATP13A2 WT and mutant V5-tagged constructs in transiently
transfected SH-SY5Y cells. GFP was co-transfected with the ATP13A2s as a transfection control. The proteasome inhibitor MG132 (10 lM) stabilizes PARK9 mutants after 24 h.
The antibody against p53, whose degradation is known to dependent to proteasome, is used as a control for MG132 treatment. Densitometry analysis indicates the steady
state protein levels of each variant. Data are represented as percent of WT. Error bars, S.E.M. n = 3. ⁄⁄P < 0.01 vs WT.
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of the life span relative to WT/WT and to WT/mt ﬁsh (Fig. 4F). The
body weight of mt/mt ﬁsh was normal (Fig. 4G). We examined the
internal organs includingbrains of the deadmt/mtﬁsh, butwe could
not identify a speciﬁc reason for the shorter lifespan ofmt/mtmeda-
ka ﬁsh. We next quantiﬁed spontaneous swimming movement in
mt/mt medaka ﬁsh. At 4 months, mt/mt ﬁsh exhibited a mild loco-
motor increase with signiﬁcant differences reported only in swim-ming duration whereas distance and velocity are normal. All the
genotypes showed comparable movement at 12 months, irrespec-
tive of atp13a2 genotype (Fig. 4H).
Collectively, we generated atp13a2mutant medaka ﬁsh carrying
almost identical mutation to human KRS/PARK9 patient. The homo-
zygousmutantﬁshgrewnormally, but relative towild-typeandhet-
erozygous animals, these mutants exhibited more spontaneous
swimming movement at 4 months and had a shorter life span.
Fig. 3. Suppression of ATP13A2 leads to cathepsin D deﬁciency and accumulation of ﬁngerprint-like structures in SH-SY5Y cells. (A) Immunoblotting with anti-ATP13A2
antibody (left panel), anti-V5 antibody (middle panel) and anti-ATP13A2 antibody (preabsorbed) (right panel) shows the ATP13A2 expression levels of SH-SY5Y cells, HepG2
cells and SH-SY5Y cells stably expressing WT (SH-WT). Cells are transfected with negative control (CT) or ATP13A2 siRNA (KD) for 72 h. (B) Immunoblotting using anti-
ATP13A2 antibody and cell growth assay of SH-SY5Y cell lines stably expressing shRNA against human ATP13A2. The graph shows the growth rate of cells. Data are the means
of triplicate experiments. Error bars, S.E.M. ⁄P < 0.05. (C) Measurement of cathepsin D, B and L activity and protein level in the extracts from ATP13A2-knockdown SH-SY5Y
cells. Enzyme activity assays were performed in three independent experiments. Error bars, S.E.M. ⁄P < 0.05. ⁄⁄P < 0.01. (D) Electron microscopic examination of SH-SY5Y cells
that stably express shATP13A2-1 or shATP13A2-2. The diminished ATP13A2 expression induces lysosome-like bodies that contain granular deposits and ﬁngerprint-like
structure. Boxed areas (d) are shown enlarged in the left (e). (E) Evaluation of LC3 accumulation using anti-LC3B antibody in SH-SY5Y cell lines stably expressing shATP13A2
(each 3 clones). ⁄⁄P < 0.01.
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Selective and progressive loss of dopaminergic/noradrenergic
cells constitutes the characteristic pathology of human PD patients.
Having previously identiﬁed TH-positive (TH+) dopaminergic neu-
rons and noradrenergic neurons in the medaka brain [17], we could
examine histologically these TH+ neurons in the brain tissue of
atp13a2 mutants. At 4 months, the number of TH+ neurons did
not differ signiﬁcantly among mt/mt, mt/WT, and WT/WT ﬁsh.
However at 8 and 12 months, the number of TH+ neurons in the
middle diencephalon and the density of TH+ ﬁbers in the telen-
cephalon were lower in the mt/mt medaka than in mt/WT or in
WT/WT ﬁsh (Fig. 5A). The mt/mt medaka ﬁsh at these stages also
had fewer noradrenergic neurons in the medulla oblongata than
did mt/WT or WT/WT ﬁsh (Fig. 5A). The reduction of TH+ neurons
was not robust but age-dependent and progressive. Additionally,we examined tryptophan hydroxylase and serotonin levels via
immunohistochemistry; neither the number of tryptophan
hydroxylase positive neurons in the raphe nor the intensity of sero-
tonin signals in the diencephalon differed signiﬁcantly among all
the genotypes (Fig. 5A). Although no TUNEL-positive dopaminergic
neuron was observed in the WT/WT brains, a few TUNEL/TH dou-
ble positive neurons were detected in the mt/mt brains (Fig. 5B). To
exclude the possibility of developmental disorder of the dopami-
nergic neurons, we also counted the TH+ neurons in the middle
diencephalon at 1 month. At this larval stage, mt/mt ﬁsh showed
comparable number of dopaminergic neurons to WT/WT ﬁsh
(Fig. S5) indicating the loss of dopaminergic neurons seen at 8
and 12 months was indeed late-onset phenotype. Next, we mea-
sured the amount of dopamine, noradrenaline, and serotonin in
whole-brain samples from mutant ﬁsh at 4 and 12 months. The
amount of dopamine in the brain samples from mt/mt medaka
Fig. 3. (continued)
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but lower than that in the WT/WT or the WT/mt at 12 months
(Fig. 5C, upper). The noradrenaline in mt/mt medaka brain samples
also tended to be lower at 12 months, but the differences were not
statistically signiﬁcant (Fig. 5C, middle). The amount of serotonin
in whole-brain samples did not differ signiﬁcantly among the
genotypes (Fig. 5C, lower). Taken together, these ﬁndings indicated
that atp13a2 homozygous mutant medaka ﬁsh showed selective
and progressive loss of dopaminergic/noradrenergic neurons, and
such loss is a typical feature of human PD.
To examine in further detail the pathology associated with the
apt13a2 mutation, middle diencephalon samples from mt/mt, mt/
WT, and WT/WT animals were analyzed via transmission electron
microscopy as described previously [18]. Structures resembling
ﬁngerprints-proﬁle, like those seen in ATP13A2-knockdown SH-
SY5Y cells, were observed in thin sections taken from each mt/mt brain examined (Fig. 5D). However, these structures were not
observed in the sections taken from WT/WT or WT/mt medaka
brain samples. Fingerprint-proﬁles have been observed in cathep-
sin D-deﬁcient mice [15] and in human patients with neuronal cer-
oid lipofuscinosis [19–21], and these structures are thought to
indicate an autophagy/lysosome disorder. We used western blots
to measure the amount of cathepsin D protein in brain tissue sam-
ples, and we found that mt/mt ﬁsh had less cathepsin D protein
than did mt/WT or WT/WT ﬁsh (Fig. 5E and S6). We also showed
that mt/mt medaka brain tissue, like the ATP13A2-knockdown
cells, exhibited a signiﬁcant reduction in cathepsin D activity
(Fig. 5E). However, cathepsin K activity, cathepsin H activity, and
proteasome activity were not affected by the atp13a2 mutation
(Fig. 5E), indicating the dysfunction of lysosomal enzymes was rel-
atively speciﬁc to cathepsin D. Alpha-synuclein accumulation is
one of the speciﬁc characters of idiopathic PD patients, Thus, we
Fig. 4. Generation of Atp13a2 mutant medaka. (A) In situ hybridization of medaka atp13a2 mRNA. Anti-sense signals and sense control of Kyoto-Cab medaka brain
(12 months). 1: telencephalon, 2: optic tectum, 3: diencephalon, 4: cerebellum, 5: medulla oblongata, 6: spinal cord. (B) Sequence data for each genotype. A = green, T = red,
G = black, and C = blue. The red arrow indicates the mutation site. This T to C mutation in the genomic sequence disrupts a splice donor site. (C) RT-PCR ampliﬁcation of
atp13a2mRNA from each genotype. WT/WTmedaka show single band, whereas WT/mt and mt/mt medaka have an additional shorter band (arrow). bp: Base pairs. The graph
indicates densitometric ratio of the shorter product/normal product. ⁄⁄⁄P < 0.001 vs. WT/WT and P < 0.01 vs. WT/mt. n = 4 for each genotype. Error bars, S.E.M. (D) Sequence of
the PCR products. The upper band indicates the normal splicing product and the lower band is the abnormal splicing product. Exon 13 skipping occurrs in the Atp13a2 mutant
medaka. (E) Real-time PCR of normal atp13a2mRNA. ⁄⁄: P < 0.01 vs. WT/WT, ⁄⁄⁄: P < 0.001 vs. WT/WT andWT/mt. n = 3 for each genotype. Error bars, S.E.M. (F) Survival curves
of each genotype. The end point is the death of each medaka or day 365. The results showmild but signiﬁcant shortening of the life span in mt/mt medaka (P < 0.001) (n = 23),
relative to that in WT/WT (n = 25) or WT/mt (n = 37). Death before 1 month stage was not counted. (G) Body weight of Atp13a2 mutant medaka at 12 months. No signiﬁcant
differences were seen (n = 20 for each group). Error bars, S.E.M. (H) Duration of swimming, total swimming distance and swimming velocity during spontaneous swimming
behavior of Atp13a2 mutant medaka (n = 15 for each group). ⁄P < 0.05 vs. WT/WT. Error bars, S.E.M.
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models. However, we could not demonstrate consistent and signif-
icant differences between ATP13A2-deﬁcient models and controls
(Figs. S3 and S7), and these ﬁndings indicated that alpha-synuclein
accumulation might not be the causative roles of KRS/PARK9.
In sum, atp13a2 homozygous mutant medaka exhibited dopa-
minergic neurodegeneration, a deﬁciency of cathepsin D, and
abnormal lysosome-related structures in the brain.
3. Discussion
Findings from previous studies clearly indicate that PARK gene
products associate with each other via protein degradation path-
ways including the autophagy–lysosome system. Indeed, dysfunc-
tion of protein degradation has emerged as an important
contributor to nigral neuronal death in PD. Presence of Lewy bodies
is strong evidence of impaired protein degradation in PD. Lewy
bodies consist of aggregated proteins, and alpha-synuclein is a ma-
jor component of these structures [22]. Thus aggregation of alpha-
synuclein has emerged as one of the most important processes in
nigral degeneration in PD. Although soluble alpha-synuclein isdegraded both during autophagy and by the proteasome, aggre-
gated alpha-synuclein is degraded and cleared mainly via the
autophagy–lysosome pathway [23]. Other PARK gene products,
speciﬁcally Parkin and PINK1, work together to clear damaged
mitochondria from cells via mitochondria-speciﬁc autophagy
called mitophagy [24]. Furthermore, ATP13A2 mainly localizes to
lysosomes, as we and other groups demonstrated [3,10–14,25]. Re-
cently, mutations in the gene encoding glucocerebrosidase (GBA), a
lysosomal enzyme, have been shown to be signiﬁcant genetic risk
factors for PD [26]. These observations indicate that lysosomal
function is important for the maintenance of dopamine neurons,
and they led us to investigate the function of ATP13A2 in the path-
ophysiology of KRS/PARK9.
ATP13A2 deﬁciency resulted in an abnormal aggregation of
lysosomes at perinuclear site. Furthermore, these accumulated
vesicles were enlarged, as previously reported [27]. Moreover, we
found evidence of lysosomal dysfunction in that cathepsin D activ-
ity was, speciﬁcally, reduced in ATP13A2-knockdown cells. Cathep-
sin D is a ubiquitously expressed lysosomal protease that is
involved in proteolytic degradation, cell invasion, and apoptosis.
Cathepsin D deﬁciencies cause neuronal ceroid lipofuscinosis, a
Fig. 5. Neuropathology of Atp13a2 mutant medaka. (A) Axial sections of telencephalon (upper) and middle diencephalon (middle and lower) of medaka brain at 12 months.
Arrows indicate TH+ ﬁbers and neurons. The lower ﬁgures are the enlarged image of middle ﬁgures. The graphs indicate the number of TH+ neurons in the middle
diencephalon (upper) and medulla oblongata (middle) and the number of tryptophan-hydroxylase positive (TPH+) neurons in the raphe. ⁄P < 0.05 vs. WT/WT and WT/mt.
⁄⁄P < 0.01 vs. WT/WT. (n = 16 for each group). Error bars, SEM. (B) TUNEL assay in medaka brain at 12 months. White arrow indicates one TUNEL/TH double positive neuron in
the middle diencephalon of mt/mt ﬁsh. The graph shows the number of TH/TUNEL double positive neurons in the middle diencephalon (n = 3). ⁄P < 0.05 vs. WT/WT. (C)
Amount of dopamine (upper), noradrenaline (middle), and serotonin (lower) in the brain of Atp13a2 mutant medaka. All values are expressed as a percentage of the amount
(ng) per protein weight (mg) for WT/WT (n = 8 for each group). ⁄P < 0.05 vs. WT/WT. Error bars, S.E.M. (D) Fingerprint-like structures in Atp13a2 mutant medaka brain.
Arrows indicate ﬁngerprint-like structures in mt/mt brain. The right ﬁgures are the high magniﬁcation images of these structures. (E) Enzyme activity (Cathepsin D, H, K and
proteasome activity) in the medaka brain. ⁄⁄⁄P < 0.001 vs. WT/T and WT/mt. Error bars, SEM. Image of a western blot shows cathepsin D protein in the medaka brain. Cross
reactivity of the antibody against medaka cathepsin D is shown in the supplementary information (Fig. S5).
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Using electronmicroscopy, we also detected lysosome like body
and granular deposits. Interestingly, we observed subcellular struc-
tures that resemble ﬁngerprint-proﬁle, and these structures
resemble abnormal structures in the neurons of cathepsin
D-deﬁcient mice [15] and in human patients with neuronal ceroid
lipofuscinosis [19–21] or with sphingolipidoses [31,32]. These re-
sults indicate that the primary cause of KRS/PARK9 is a lysosomal
dysfunction and KRS/PARK9 could also be classiﬁed into a ‘‘lyso-
some disease’’.
We have recently used medaka ﬁsh to develop an animal model
of PD [17,18,33,34]. Here, we found a mutation in our TILLING li-
brary that is almost identical to a PD-associated mutation in hu-
man patients. This medaka mutation results in the same
abnormal splicing that is seen in the human patients with KRS/
PARK9. Homozygous mutant ﬁsh exhibited selective loss of dopa-
minergic and noradrenergic neurons; this type of neuron loss is a
pathology typically seen in human PD patients. Additionally, we
found that tissues and cells in the brains from homozygous mutant
medaka exhibited a speciﬁc reduction of cathepsin D protein and
developed ﬁngerprint-like subcellular structures. Both ﬁndings
strongly indicate that the ATP13A2 mutation could lead to the dys-
function of lysosomes in medaka neurons.
Recently, Fonseca et al. injected Morpholinos against atp13a2
into zebraﬁsh embryo and showed that loss of Atp13a2 results in
embryonic lethality [35]. As they also showed in zebraﬁsh, atp13a2mRNA expressed not only in the brain but also in the entire body in
medaka larvae (data not shown). This suggested that Atp13a2 is
also important for some unknown function in other organs than
the central nervous system. Our medaka model mimics the human
mutation and showed pronounced reduction of atp13a2mRNA but
not null expression. This might be helpful to study the long-term
effect of Atp13a2 dysfunction.
As is the case of human patients with PD, cell death was speciﬁc
to dopamine and noradrenaline neurons in our medaka model of
KRS/ATP13A2. This cell-type speciﬁcity is also evident with our
other medaka models of PD, including the models resulting from
a lysosome inhibitor treatment [18,34]. The atp13a2 mRNA, like
other PD-related mRNAs, is expressed ubiquitously in the medaka
brain [33]. Thus, the expression pattern of atp13a2 could not ex-
plain the selective cell death in our model. Dopamine neurons con-
tain toxic proteins derived from dopamine itself [36,37], and
lysosomal function is essential in these neurons for preventing
accumulation of the toxic proteins and other toxic metabolic prod-
ucts. Therefore, we speculate that dopamine neurons are especially
vulnerable to lysosome dysfunction.
One negative ﬁnding is that mutant ﬁsh did not show slow lo-
comotive movement, as do human PD patients. Based on our anal-
ysis, it seemed that the mutant ﬁsh swam the same amount, or
more, than did control ﬁsh. In humans, loss of at least 80% of the
dopaminergic neurons in substantia nigra seems necessary to
evoke clear PD symptoms. The extent of the loss of dopaminergic
1324 H. Matsui et al. / FEBS Letters 587 (2013) 1316–1325neurons in our medaka model might not be enough to evoke loco-
motive impairment. The mild increase of locomotion at 4 months
seen in homozygous mutant might have a relation with the non-
signiﬁcant increase of dopamine at the same stage. Similar tenta-
tive increase of dopamine at younger stage is also observed in an-
other PDmodel ﬁsh [33]. Such increased dopamine might harm the
neurons, because the metabolism of dopamine is accompanied by
the generation of oxidative radicals [38].
In conclusion, we demonstrated that reduction in ATP13A2
function in vitro or in vivo resulted in dysfunction of cathepsin D
and the appearance of abnormal structures that are associated
with lysosomal disorders. We used a teleost ﬁsh, medaka, to suc-
cessfully generate an animal model suffered selective degeneration
of dopaminergic neurons. Our ﬁndings indicate that lysosome-
mediated autophagy may play a key role to protect dopaminergic
neurons.
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